It launched an “affordable drugs” campaignExternal link to pressure the Swiss Federal Council to introduce compulsory licencing, an instrument which allows cheaper generic medications to be introduced to the market despite the existence of a patent.
Public Eye argues the Swiss government has for too long put the interest of the pharmaceutical industry before the needs of the patients both in Switzerland and abroad.
It accused the authorities of being influenced by the “aggressive lobbying carried out by large Basel-based companies,” which are responsible for sky-rocketing prices.
Introducing compulsory licensing in Switzerland would make the Swiss healthcare system more sustainable, “send a strong signal to the international community and allow access to essential drugs for millions of people”, Public Eye wrote.
The appeal is backed by the Swiss Cancer League, numerous experts in the field and well-known Swiss politicians, such as former Federal Councillor Ruth Dreifuss.
More
More
Wanted: Pharma super cops
This content was published on
Have experience in tackling cybercrime, extremism, extortion, blackmail and bribery? If yes, the Swiss pharma industry might want to hear from you.
Swiss invention: 90-year anniversary of first T-bar ski lift
This content was published on
On Monday it will be 90 years since the world’s first T-bar ski lift went into service in Davos. This Swiss invention was an instant success.
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss pharma suspected of delaying generic competition
This content was published on
The United States Food and Drug Administration (FDA) lists Novartis and Roche among drug-makers suspected of hindering generic competition.
This content was published on
Each year, some half a million people die of malaria, many of them children. Switzerland is a world leader in research to combat the disease.
This content was published on
Links between parliamentarians in Bern and lobby groups have grown by 20% between 2007 and 2015, according to a new study.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.